[go: up one dir, main page]

AU2001258489A1 - Novel vitronectin receptor antagonists - Google Patents

Novel vitronectin receptor antagonists

Info

Publication number
AU2001258489A1
AU2001258489A1 AU2001258489A AU5848901A AU2001258489A1 AU 2001258489 A1 AU2001258489 A1 AU 2001258489A1 AU 2001258489 A AU2001258489 A AU 2001258489A AU 5848901 A AU5848901 A AU 5848901A AU 2001258489 A1 AU2001258489 A1 AU 2001258489A1
Authority
AU
Australia
Prior art keywords
vitronectin receptor
receptor antagonists
novel
formula
novel vitronectin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001258489A
Inventor
Jacques Demassey
Jean-Francois Gourvest
Jean-Michel Lefrancois
Jean-Marie Ruxer
John Bernard Weston
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Publication of AU2001258489A1 publication Critical patent/AU2001258489A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention concerns vitronectin receptor antagonist compounds of formula (I): R1-Y-A-B-D-E-F-G wherein R1, Y, A, B, D, E, F, and G are as defined in the description, their physiologically acceptable salts and their prodrugs, methods for preparing compounds of formula (I), their use, in particular as medicine and pharmaceutical compositions containing them.
AU2001258489A 2000-05-09 2001-05-04 Novel vitronectin receptor antagonists Abandoned AU2001258489A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0005859A FR2808798A1 (en) 2000-05-09 2000-05-09 New N-heterocyclyl-aminoacid derivatives and analogs, are vitronectin analogs useful e.g. for treating osteoporosis, tumor growth or metastasis, inflammation or cardiovascular disease
FR0005859 2000-05-09
PCT/FR2001/001357 WO2001085729A1 (en) 2000-05-09 2001-05-04 Novel vitronectin receptor antagonists

Publications (1)

Publication Number Publication Date
AU2001258489A1 true AU2001258489A1 (en) 2001-11-20

Family

ID=8850000

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001258489A Abandoned AU2001258489A1 (en) 2000-05-09 2001-05-04 Novel vitronectin receptor antagonists

Country Status (12)

Country Link
US (1) US6838453B2 (en)
EP (1) EP1282621B1 (en)
JP (1) JP5143989B2 (en)
AT (1) ATE304012T1 (en)
AU (1) AU2001258489A1 (en)
CA (1) CA2408293A1 (en)
DE (1) DE60113248T2 (en)
ES (1) ES2249431T3 (en)
FR (1) FR2808798A1 (en)
IL (1) IL152613A0 (en)
MX (1) MXPA02011043A (en)
WO (1) WO2001085729A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3332679B2 (en) 1995-08-08 2002-10-07 昭和電工株式会社 Die for joint extrusion
PL371841A1 (en) * 2004-12-20 2006-06-26 ADAMED Sp.z o.o. New derivatives of 3-phenylpropionic acid
PL372332A1 (en) * 2005-01-19 2006-07-24 ADAMED Sp.z o.o. New compounds, derivatives of 3-phenylpropionic acid
PL372356A1 (en) * 2005-01-20 2006-07-24 ADAMED Sp.z o.o. New compounds, derivatives of 3-phenylpropionic acid
AU2017292754B2 (en) * 2016-07-05 2021-06-17 Icahn School Of Medicine At Mount Sinai Tetrahydronaphthyridinepentanamide integrin antagonists

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5296486A (en) * 1991-09-24 1994-03-22 Boehringer Ingelheim Pharmaceuticals, Inc. Leukotriene biosynthesis inhibitors
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
DE19629816A1 (en) * 1996-07-24 1998-01-29 Hoechst Ag New cycloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists
DE19629817A1 (en) * 1996-07-24 1998-01-29 Hoechst Ag New imino derivatives as inhibitors of bone resorption and vitronectin receptor antagonists
EP0933367A1 (en) * 1997-12-19 1999-08-04 Hoechst Marion Roussel Deutschland GmbH Novel acylguanidine derivates as inhibitors of bone resorption and as vitronectin receptor antagonists
UA63990C2 (en) * 1998-01-23 2004-02-16 Авентіс Фарма Дойчланд Гмбх Novel sulfonamide derivatives as bone tissue resoprtion inhibitors and cells adhesion inhibitors
HUP0101143A3 (en) * 1998-03-10 2002-12-28 Smithkline Beecham Corp Pyridin-carboxylic acid derivatives as vitronectin receptor antagonists, process for producing them and pharmaceutical compositions containing them
ATE253061T1 (en) * 1998-06-29 2003-11-15 Iaf Biochem Int THIOPHENE AND FURAN-2,5-DICARBOXAMIDE USEFUL IN THE TREATMENT OF CANCER
WO2000017197A1 (en) * 1998-09-21 2000-03-30 Biochem Pharma Inc. Quinolizinones as integrin inhibitors
GB9821061D0 (en) * 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds

Also Published As

Publication number Publication date
ATE304012T1 (en) 2005-09-15
WO2001085729A1 (en) 2001-11-15
FR2808798A1 (en) 2001-11-16
CA2408293A1 (en) 2001-11-15
DE60113248D1 (en) 2005-10-13
IL152613A0 (en) 2003-06-24
JP2003532732A (en) 2003-11-05
MXPA02011043A (en) 2003-03-10
EP1282621B1 (en) 2005-09-07
EP1282621A1 (en) 2003-02-12
US6838453B2 (en) 2005-01-04
DE60113248T2 (en) 2006-06-29
JP5143989B2 (en) 2013-02-13
ES2249431T3 (en) 2006-04-01
US20040225111A1 (en) 2004-11-11

Similar Documents

Publication Publication Date Title
MY122392A (en) Adamantane derivatives of use of p2x7 receptor antagonists, a process for their preparation, pharmaceutical compositions containing them and a process for preparing the pharmaceutical compositions
ATE316083T1 (en) ADAMANTANDE DERIVATIVES
ZA200700765B (en) Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol
SE9904505D0 (en) Novel compounds
MY138086A (en) Novel urea derivative as vanilloid receptor-1 antagonist
SE9901875D0 (en) Novel compounds
MX2009006018A (en) Quinuclidinol derivatives as muscarinic receptor antagonists.
PL361361A1 (en) Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
MXPA04002338A (en) Carbazole derivatives and their use as npy5 receptor antagonists.
TW200505823A (en) CaSR antagonist
MXPA04001968A (en) Oral antidiabetic agents.
DE602004011966D1 (en) Heterocyclylverbindungen
PL372457A1 (en) New pharmaceutical compositions containing flibanserin polymorph a
WO2003053945A3 (en) Urea derivatives and their use as vanilloid receptor antagonists
GB0109122D0 (en) Novel compounds
TW200639156A (en) New compounds
MXPA05013050A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof.
GEP20104964B (en) 3-aminocarbazole compounds, pharmaceutical composition containing the same and method for the preparation thereof
MXPA04005313A (en) Aminotetralin derivatives as muscarinic receptor antagonists.
WO2001010860A3 (en) Quinazolinone and azaquinazolinone derivatives
MXPA04005484A (en) Method for preparing echinocandin derivatives.
AU2001258489A1 (en) Novel vitronectin receptor antagonists
MXPA05011841A (en) Methyl indoles and methyl pyrrolopyridines as alph-1 adrenergic agonists.
MXPA05005340A (en) Novel vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same.
SE0202693D0 (en) Compounds